BioMarin Pharmaceutical Inc. Share Price Today: Live Updates & Key Insights

BioMarin Pharmaceutical Inc. share price today is $54.14, up -1.64%. The stock opened at $54.99 against the previous close of $55.03, with an intraday high of $55.71 and low of $53.89.

BioMarin Pharmaceutical Inc. Share Price Chart

BioMarin Pharmaceutical Inc.

us-stock
To Invest in {{usstockname}}
us-stock

BioMarin Pharmaceutical Inc. Share Price Performance

$54.14 -0.0164(-1.64%) BMRN at 23 Mar 2026 12:16 PM Biotechnology
Lowest Today 53.89
Highest Today 55.71
Today’s Open 54.99
Prev. Close 55.03
52 Week High 73.18
52 Week Low 50.76
Day’s Range: Low 53.89 High 55.71
52-Week Range: Low 50.76 High 73.18
1 day return -
1 Week return -5.72
1 month return -13.65
3 month return -8.7
6 month return +0.35
1 year return -24.78
3 year return -39.97
5 year return -31.01
10 year return -

BioMarin Pharmaceutical Inc. Institutional Holdings

BlackRock Inc 11.46

Vanguard Group Inc 9.43

Dodge & Cox 7.58

PRIMECAP Management Company 7.57

Dodge & Cox Stock I 5.08

State Street Corp 4.56

NORGES BANK 3.92

AQR Capital Management LLC 3.48

iShares Core S&P Mid-Cap ETF 3.23

Vanguard Total Stock Mkt Idx Inv 3.15

Viking Global Investors LP 3.14

Vanguard PRIMECAP Inv 2.75

Vanguard Capital Opportunity Inv 2.71

Vanguard Small Cap Index 2.26

Geode Capital Management, LLC 1.91

Dimensional Fund Advisors, Inc. 1.73

Millennium Management LLC 1.58

Vestal Point Capital LP 1.56

Capital Research Global Investors 1.32

R-co Valor C EUR 1.29

Vanguard Small Cap Growth Index Inv 1.26

The Goldman Sachs Group Inc 1.19

Vanguard Institutional Extnd Mkt Idx Tr 1.08

FMR Inc 0.96

Squarepoint Ops LLC 0.95

State Street® SPDR® S&P® Biotech ETF 0.94

American Funds Capital World Gr&Inc A 0.88

Capital Group World Growth & Inc Cmp 0.88

Northern Trust Corp 0.86

UBS Group AG 0.80

Qube Research & Technologies 0.75

PRIMECAP Odyssey Aggressive Growth 0.74

Charles Schwab Investment Management Inc 0.74

iShares Biotechnology ETF 0.74

State Street® SPDR® S&P MIDCAP 400® ETF 0.72

First Trust NYSE Arca Biotech ETF 0.72

Fidelity Contrafund 0.61

State St Russell Sm/Mid Cp® Indx SL Cl I 0.58

DNB Global A 0.53

Fidelity Extended Market Index 0.52

BioMarin Pharmaceutical Inc. Market Status

Strong Buy: 16

Buy: 7

Hold: 6

Sell: 0

Strong Sell: 0

BioMarin Pharmaceutical Inc. Fundamentals

Market Cap 10410.46 M

PB Ratio 1.7109

PE Ratio 30.0722

Enterprise Value 9459.56 M

Total Assets 7594.02 M

Volume 4353476

BioMarin Pharmaceutical Inc. Company Financials

Annual Revenue FY25:3221253000 3221.3M, FY24:2853915000 2853.9M, FY23:2310557000 2310.6M, FY22:2096039000 2096.0M, FY21:1846275000 1846.3M

Annual Profit FY25:2484425000 2484.4M, FY24:2273680000 2273.7M, FY23:1803891000 1803.9M, FY22:1612370000 1612.4M, FY21:1375760000 1375.8M

Annual Net worth FY25:348901000 348.9M, FY24:426859000 426.9M, FY23:147021000 147.0M, FY22:141561000 141.6M, FY21:-64080000 -64.1M

Quarterly Revenue Q3/2025:874565000 874.6M, Q2/2025:825410000 825.4M, Q1/2025:745145000 745.1M, Q4/2024:747313000 747.3M, Q3/2024:745740000 745.7M

Quarterly Profit Q3/2025:579470000 579.5M, Q2/2025:675320000 675.3M, Q1/2025:593587000 593.6M, Q4/2024:611174000 611.2M, Q3/2024:557283000 557.3M

Quarterly Net worth Q3/2025:-46573000 -46.6M, Q2/2025:240532000 240.5M, Q1/2025:185686000 185.7M, Q4/2024:124943000 124.9M, Q3/2024:106080000 106.1M

About BioMarin Pharmaceutical Inc. & investment objective

Company Information BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Organisation Biotechnology

Employees 3221

Industry Biotechnology

CEO Mr. Alexander Hardy

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

BioMarin Pharmaceutical Inc. FAQs

What is the share price of BioMarin Pharmaceutical Inc. today?

The current share price of BioMarin Pharmaceutical Inc. is $54.14.

Can I buy BioMarin Pharmaceutical Inc. shares in India?

Yes, Indian investors can buy BioMarin Pharmaceutical Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy BioMarin Pharmaceutical Inc. shares in India?

You can easily invest in BioMarin Pharmaceutical Inc. shares from India by:

Can I buy fractional shares of BioMarin Pharmaceutical Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of BioMarin Pharmaceutical Inc.?

BioMarin Pharmaceutical Inc. has a market cap of $10410.46 M.

In which sector does BioMarin Pharmaceutical Inc. belong?

BioMarin Pharmaceutical Inc. operates in the Biotechnology sector.

What documents are required to invest in BioMarin Pharmaceutical Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of BioMarin Pharmaceutical Inc.?

The PE ratio of BioMarin Pharmaceutical Inc. is 30.07 and the PB ratio is 1.71.